Recent Finacing
Recent Raise
Replimune develops Immulytic oncolytic immunotherapies using selective viral replication for tumor killing and delivering immune-activating proteins to tumors and lymph nodes, advancing RP1 into clinical trials and checkpoint combinations.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors